|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
���� |
|
���� |
|
Ƥ������ |
| ��������������� | |
|
���� |
|
���� |
|
����� |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
�����ÿ�����Ƥ���Ƶ�Ӧ��
����, ����, �����
���ľ�ҽ��ѧ����ҽԺȫ��Ƥ���Բ����� ���� 710032
����������һ����Ч�ߡ�������ǿ�������ֶ�,���Ż��̿���ij��ֺͼ����������,Խ��Խ��������ÿ�������ʵ���о������ٴ�Ӧ�á���Ҫ�����������ÿ�������û��Ƽ���������м���������֯����Ƥ��������Ƥ��������Ч��
[2] Glennie MJ,Johnson PW.Clinical trials of antibody therapy.Immunol Today,2000,21(8):403-410.
[3] Mehrabi D,DiCario JB,Soon SL,et al.Advances in the management of psoriasis:monoclonal antibody therapies,lnt J Dermatol,2002,41(12):827-835.
[4] Clynes RA,Towers TL,Presta LG,et al.Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.Nat Med,2000,6(4):443-446.
[5] Shah D,Ledbetter JA,Press OW.Signaling events involved in antiCD20-induced apoptosis of malignant human B cells.Cancer Immunol Immunother,2000,48(12):673-683.
[6] Berger MS,Leopold LH,Dowell JA,et al.Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse.Invest New Drugs,2002,20(4):395-406.
[7] Gottlieb AB,Lebwohl M,Shirin S,et al.Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris:results of a pilot,muhicenter,multiple-dose,placebo-controlled study.J Am Acad Dermatol,2000,43(4):595-604.
[8] Singri P,West DP,Gordon KB.Biologic therapy for psoriasis:the new therapeutic frontier.Arch Dermatol,2002,138(5):657-663.
[9] 0gilvie AL,Antoni C,Dechant C,et al.Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.Br J Dermatol,2001,144(3):587-589.
[10] Tan MH,Gordon M,Lebwohl O,et al.Improvement of Pyodenna gangrenosum and psoriasis associated with Crohn disease with antitumor necrosis factor alpha monoclonal antibody.Arch Dermatol,2001,137(7):930-933.
[11] Hassard PV,Binder SW,Nelson V,et al.Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease:a case report.Gastroenterology,2001,120(4):995-999.
[12] Kaplan M.Eculizumab(Alexion).Curt Opin Investig Drugs,2002,3(7):1017-1023.
[13] Hollenbaugh D,Mischel-Petty N,Edwards CP,et al.Expression of functional CD40 by vascular endothelial cells.J Exp Med,1995,182(1):33-40.
[14] Kalunian KC,Davis JC Jr,Merrill JT,et al.Treatment of systemic lupus erythematosus by inhibition of T cell eostimulation with antiCD154:a randomized,double-blind,placebo-controlled trial.Arthritis Rheum,2002,46(12):3251-3258.
[15] Knox S,Hoppe RT,Maloney D,et al.Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody.Blood,1996,87(3):893-899.
[16] Paul T,Radny P,Krober SM,et al.Intralesional rituximab for cutaneous B-cell lymphoma.Br J Dermatol,2001,144(6):1239-1243.
[17] Prewett M,Huber J,Li Y,et al.Antivaseular endothelial growth factor receptor(fetal liver kinase1)monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.Cancer Res,1999,59(20):5209-5218.
[18] Huang S,Mills L,Mian B,et al.Fully humanized neutralizing antibodies to intedeukin-8(ABX-IL8)inhibit angiogenesis,tumor growth,and metastasis of human melanoma.Am J Pathol,2002,161(1):125-134.
[19] Nasi ML,Meyers M,Livingston PO,et al.Anti-melanoma effects of R24,a monoclonal antibody against GD3 ganglioside.Melanoma Res,1997,7(Suppl2):S155-162.
[20] Foon KA,Lutzky J,Baral RN,et al.Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.J Clin Oncol,2000,18(2):376-384.
[21] Jaeobson JM,Lowy I,Fletcher CV,et al.Single-dose safety,pharmacology,and antiviral activity of the human immunodeficiency virus(HIV)type 1 entry inhibitor PRO 542 in HIV-infected adults.J Infect Dis,2000,182(1):326-329.
[22] Stiegler G,Armbruster C,Vcelar B,et al.Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans:a phase I evaluation.AIDS,2002,16(15):2019.